Creative Medical Technology Holdings (CELZ) Non-Current Debt (2016 - 2017)
Creative Medical Technology Holdings (CELZ) posted quarterly Non-Current Debt of $25000.0 for Q1 2017, up 37.36% year-over-year from $18200.0 in Q1 2016, and little changed quarter-over-quarter from $25000.0 in Q4 2016.
Creative Medical Technology Holdings (CELZ) Non-Current Debt (2016 - 2017) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Non-Current Debt for 2 consecutive years, with $25000.0 the latest figure, recorded in Q1 2017.
- In Q1 2017, Non-Current Debt rose 37.36% year-over-year to $25000.0; the TTM figure through Mar 2017 stood at $25000.0 (up 37.36% YoY), while the FY2016 annual figure was $25000.0, changed N/A from the prior year.
- Non-Current Debt steadied at $25000.0 in Q1 2017 per CELZ's latest filing, from $25000.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $69031.0 in Q2 2016 and bottomed at $18200.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 25,000.00 |
| Dec 31, 2016 | 25,000.00 |
| Sep 30, 2016 | 25,000.00 |
| Jun 30, 2016 | 69,031.00 |
| Mar 31, 2016 | 18,200.00 |